Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Organon Acquires Large-Molecule Cannabinoid Receptor Agonist Technology From Kadmus

This article was originally published in The Pink Sheet Daily

Executive Summary

Kadmus’ large-molecule approach dovetails with Organon’s small-molecule work to develop drug candidates based on fatty acid amide hydrolase technology, Organon exec David Nicholson tells “The Pink Sheet” DAILY.
Advertisement

Related Content

CeNeRx Biopharma Licenses Cannabinoid Compounds To Study For CNS Indications
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
Schering-Plough Makes Its Move, Snapping Up Organon For $14.4 Billion
GW Licenses U.S. Sativex Rights To Otsuka In $273 Million Deal
Valeant Plans New Sales Strategy For Cesamet; Ends Deal With Par

Topics

Advertisement
UsernamePublicRestriction

Register

PS066247

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel